Whole disease journey management in the diagnosis and treatment of pancreatic cancer

doi:10.3969/j.issn.1009-976X.2021.01.001

Lingnan Modern Clinics In Surgery ›› 2021, Vol. 21 ›› Issue (01): 1-5.DOI: 10.3969/j.issn.1009-976X.2021.01.001

• Comment • Next Articles

Whole disease journey management in the diagnosis and treatment of pancreatic cancer

LOU Wen-hui

Department of Pancreatic Surgery, Cancer Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China

重视胰腺癌诊治的全流程管理

楼文晖

复旦大学附属中山医院胰腺外科、复旦大学附属中山医院肿瘤防治中心,上海 200032

通讯作者: 楼文晖,Email：lou.wenhui@zs_hospital.sh.cn
作者简介:楼文晖,医学博士，主任医师，教授，博士生导师
复旦大学附属中山医院胰腺外科主任、普外科副主任、外科中心实验室主任。上海市优秀学科带头人，上海医学会普外科分会前任主任委员。现任上海医学会外科分会副主任委员，中华医学会第十八届外科委员会全国委员、中华医学会外科学分会胰腺外科学组副组长、中国研究型医院协会胰腺病分会副会长、中国医师协会外科分会全国委员、中国医师协会胰腺病专业委员会常委，MDT专业委员会常委；神经内分泌肿瘤分委会主任委员；中国医促会神经内分泌肿瘤分会、快速康复委员会、减重及代谢外科分会副会长；中国医学装备协会外科装备分会基础装备专委会主任委员。《岭南现代临床外科》杂志副主编、《Journal of Digestive Disease》、《Annual of Surgery》（中文版）、《中国实用外科杂志》、《中华肝胆外科杂志》，《中华医学杂志》、《中华外科杂志》、《中华消化外科杂志》的编委和通讯编委。
近年来以第一作者和通讯作者在国内核心期刊和国外杂志发表文章一百多篇，其中SCI论文六十余篇。承担多项包括国家自然科学基金，“863”项目、国家重大研发计划等多项国家级和省市级研究课题。2020年获得上海医学二等奖、先后获得“国之名医”（2019年），上海市杰出专科医师（2020年）等称号。
基金资助:
国家自然科学基金（81773068）; 科技部国家重点研发计划（2019YFC1315902）

Abstract

Abstract: The incidence of pancreatic cancer is increasing quickly, with dismal prognosis. In order to improve the long-term survival of pancreatic cancer, it is necessary to employ the disease-centered multidisciplinary model in the diagnosis and treatment. Via effective combination of multidisciplinary team to achieve the whole journey management of diagnosis, staging, precision medicine, rational operation, and supportive care. Improvement of long-term survival could be accomplished as new advances of multi-omics, tumor immunology, target therapy and chemo-radiation therapy.

Key words: pancreatic cancer, diagnosis, treatment, precision medicine

摘要： 胰腺癌的发病率逐年增高,远期疗效不佳,为了改善胰腺癌的预后,有必要推进以疾病为中心的诊疗模式,通过多学科团队的有机组合,达成早期诊断、分期、精准治疗、合理手术、对症支持治疗的全诊治流程管理,时刻跟踪和应用多组学分析、肿瘤免疫、靶向治疗和放化疗的最新进展,显著提高胰腺癌的远期疗效。

关键词: 胰腺癌, 诊断, 治疗, 精准医学

CLC Number:

R735.9

LOU Wen-hui. Whole disease journey management in the diagnosis and treatment of pancreatic cancer[J]. Lingnan Modern Clinics In Surgery, 2021, 21(01): 1-5.

楼文晖. 重视胰腺癌诊治的全流程管理[J]. 岭南现代临床外科, 2021, 21(01): 1-5.

References

[1] Liu H, Sun B, Wang S, et al.Circulating Tumor Cells as a Biomarker in Pancreatic Ductal Adenocarcinoma[J]. Cell Physiol Biochem, 2017, 42(1):373-382.
[2] Sausen M, Phallen J, Adleff V, et al.Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients[J]. Nat Commun, 2015, 6:7686.
[3] Liu X, Liu L, Ji Y, et al.Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer[J]. EbioMedicine, 2019, 41:345-356.
[4] Yang Z, LaRiviere MJ, Ko J, et al. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma[J]. Clin Cancer Res, 2020, 26(13):3248-3258.
[5] Khorana AA, Mangu PB, Berlin J, et al.Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2016, 34(21):2541-2556.
[6] Attiyeh MA, Chakraborty J, Doussot A, et al.Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis[J]. Ann Surg Oncol, 2018, 25(4):1034-1042.
[7] DreyerSB, PineseM, JamiesonNB, et al. Precision oncology in surgery: patient selection for operable pancreatic cancer[J].Ann Surg, 2020, 272(2):366-376.
[8] Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages[J]. PLoS Med, 2010, 7(4):e1000267.
[9] National Comprehensive Cancer Network.(NCCN) Clinical PracticeGuidelinesinOncology.PancreaticAdenocarcinoma,Version3 [EB/OL].[2019-11-27]. https://www.nccn.org/professionals/physician_gls/default.aspx.
[10] Paula G, Daniel H.Palmer, et al. ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer[J]. J Clin Oncol, 2020, 38(15_suppl): 4504-4504.
[11] Davendra S, Mai T.Duong, et al. SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA)[J]. J Clin Oncol, 2020, 38(15_suppl): 4504-4504.
[12] Chad A Barnes, Ashley N Krepline, Mohammed Aldakkak, et al.Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy?[J]. J Gastrointest Surg, 2017, 21(11):1793-1803.
[13] Santucci N, Facy O, Ortega-Deballon P,et al.CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients[J]. Pancreatology, 2018, 18(6):666-670.
[14] Tsai S, George B, Wittmann D,et al.Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients with Localized Pancreatic Cancer[J]. Ann Surg, 2020, 271(4):740-747.
[15] Pishvaian MJ, Bender RJ, Halverson D, et al.Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative[J]. Clin Cancer Res, 2018, 24(20):5018-5027.
[16] Golan T, Hammel P, Reni M, et al.Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer[J]. N Engl J Med, 2019, 381(4):317-327.
[17] B Schultheis, D Reuter, MP Ebert, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study[J]. Ann Oncol,2017,28(10):2429-2435.
[18] Gemenetzis G, Groot VP, Yu J, et al.Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate with Disease Status: Results of the Prospective CLUSTER Study[J]. Ann Surg, 2018, 268(3):408-420.

Whole disease journey management in the diagnosis and treatment of pancreatic cancer

重视胰腺癌诊治的全流程管理

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	HE Chong, ZHOU Shu-rui, LI Ya-qing, CHEN Shao-jie, LIAN Guo-da, CHEN Shang-xiang, HUANG Kai-hong. Screening of ferroptosis-related genes and construction of prognostic prediction model in pancreatic cancer [J]. Lingnan Modern Clinics In Surgery, 2022, 22(1): 14-23.
[2]	LIN Xing-yi, TIAN Zhen-feng, PAN Le-le, SU Ming-xin, CHEN Yin-ting. Metabolic pathways and key gene analysis of circulating tumor cells in pancreatic cancer based on GEO database [J]. Lingnan Modern Clinics In Surgery, 2022, 22(1): 34-41.
[3]	Liu Wei. Five-year follow-up analysis of clinical efficacy of radiotherapy alone and radiochemotherapy in malignant glioma [J]. Lingnan Modern Clinics In Surgery, 2022, 22(1): 89-93.
[4]	KONG Ling-qi, QU Yan-lin, ZHU Fan-he. Current status of diagnosis and treatment of testicular tumors in children [J]. Lingnan Modern Clinics In Surgery, 2021, 21(06): 684-687.
[5]	WU Zhuo-peng, YANG Jie. Prevention and treatment of chylothorax in thoracic surgery [J]. Lingnan Modern Clinics In Surgery, 2021, 21(06): 688-692.
[6]	LU Xu, LI Hua, YI Shu-hong, ZHAO Hui, ZHU Shu-guang, LI Hai-bo, YANG Yang, WANG Guo-ying. Transarterial chemoembolization combined with Lenvatinib bridging in the treatment of 2 patients with hepatocellular carcinoma exceeding Milan standard liver transplantation [J]. Lingnan Modern Clinics In Surgery, 2021, 21(05): 507-511.
[7]	HUANG Guo-hui, LIU Yan-ping, WANG Sheng-yan, ZHANG Long. Clinicopathological analysis of 56 cases of splenic metastatic tumor [J]. Lingnan Modern Clinics In Surgery, 2021, 21(05): 526-530.
[8]	LIN Zhi-wen, LIU Hong-zhi, ZENG Yong-yi. The controversies and hotspots of lymph node dissection for intrahepatic cholangiocarcinoma [J]. Lingnan Modern Clinics In Surgery, 2021, 21(04): 377-382.
[9]	ZHANG Cheng, LUO Ding-yuan, LI Hong-hao. Progress in precise diagnosis and treatment of thyroid tumors [J]. Lingnan Modern Clinics In Surgery, 2021, 21(04): 383-386.
[10]	YANG Wen-qian, LIN Wan-yi, GONG Chang. Characteristics on diagnosis and treatment of breast cancer patients with liver metastasis [J]. Lingnan Modern Clinics In Surgery, 2021, 21(03): 272-277.
[11]	GAO Zhen-hua, WANG Jun-hong, WAN Yu-ping, SHAO E-ling, WANG Xing-sheng, QIAN Hong-liang, LV Peng-xiang, RAN Ya-zhen. Clinical experience in the treatment of autoimmune pancreatitis [J]. Lingnan Modern Clinics In Surgery, 2021, 21(03): 329-332.
[12]	LI Hao-quan, YE Zhen-wei, CHEN Shi-xing, JIANG Jing-zhu, WANG Zai-guo. Diagnosis and treatment of undifferentiated sarcoma of the liver in adults： a case report and the literature review [J]. Lingnan Modern Clinics In Surgery, 2021, 21(03): 349-351.
[13]	LI Yue, LV Guo-qing. Optimized utilization of clinical and laboratory parameters in the diagnosis of acute appendicitis [J]. Lingnan Modern Clinics In Surgery, 2021, 21(02): 209-212.
[14]	HAN Shi-ji, LIAN Guo-da, CHEN Shao-jie, HUANG Kai-hong, LI Jia-jia. Construction and functional verification of immortalized human pancreatic stellate cells [J]. Lingnan Modern Clinics In Surgery, 2021, 21(01): 36-43.
[15]	YUAN Guan-ping, JIANG Zhi-min, MA Dong, PAN Zi-chun, DING Ying, XIE De-rong. FOLFIRINOX regimen versus AG regimen as first-line therapy in advanced pancreatic cancer： A multicenter observational study [J]. Lingnan Modern Clinics In Surgery, 2021, 21(01): 53-58.